AGEN
AGENUS INC
Biological Products, (No Diagnostic Substances)- 売上
- $114m
- 時価総額
- $233m
株価 $6.60 · 100株 660円
がん治療薬候補の開発と商業化を目指し医師や患者への普及を図る
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $156m | $103m | $114m |
| 成長率 | — | ▲33.8% | 10.4% |
| 総利益 | $153m | $103m | $113m |
| 総利益率 | 98.0% | 99.5% | 99.1% |
| 販管費 | $79m | $72m | $54m |
| 販管費率 | 50.4% | 69.5% | 47.6% |
| 営利 | ▲$160m | ▲$120m | ▲$20m |
| 営利率 | ▲102.1% | ▲116.4% | ▲17.7% |
| 純利益 | ▲$121m | ▲$121m | ▲$121m |
| PBR | — | — | — |
| PSR | 1.5 | 2.3 | 2.0 |
| PGPR | 1.5 | 2.3 | 2.1 |
| PER | — | — | — |
| ﾈｯﾄｷｬｯｼｭ | $63m | $28m | ▲$10m |
| EV/EBITDA | — | — | — |
| Rule of 40 | — | ▲150% | ▲7% |
| セールス効率 | — | — | — |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）